M13 Phage Display

Construction and Screening of M13 Phage Display Libraries

1. Research Background

M13 phage display technology is a core foundation in protein engineering, antibody discovery, and drug screening. By fusing foreign peptides or proteins to phage coat proteins (e.g., pIII, pVIII), this technology achieves a tight linkage between phenotype and genotype. Precise and highly diverse phage libraries provide critical tools for in-depth studies of protein–protein interactions, as well as the development of monoclonal antibodies and novel therapeutic targets.

Against this background, GeneRulor provides a one-stop M13 phage library solution covering the entire workflow from library design, synthesis, and construction to high-throughput screening. We are committed to delivering professional and reliable customized solutions for global academic and industrial clients.

2. Phage Characteristics and Biological Background

(1) Structural Properties: M13 is a filamentous phage with a single-stranded DNA (ssDNA) genome. Its coat consists of approximately 2,700 major coat proteins pVIII and five minor coat proteins pIII at the tip.

(2) Non-lytic Life Cycle: Unlike lytic phages, M13 infects Escherichia coli and releases progeny phages through secretion across the cell membrane without host cell lysis. This makes phage particles highly stable and easy to purify.

(3) Library Principle: Leveraging the genetic plasticity of M13, random sequences or specific gene fragments are inserted into coat protein genes. Each phage particle displays a unique peptide or protein on its surface, while harboring the corresponding coding sequence inside.

Figure 1 Introduction to M13 Phage

3. Library Construction and Screening Strategies

For different application scenarios (e.g., antibody libraries, peptide libraries), our mainstream technical strategies include:

3.1 pIII Display (Low-Copy Display)

(1) Mechanism: Foreign sequences are fused to the N-terminus of the pIII protein.

(2) Advantages: Each phage displays only 1–5 copies, suitable for screening high-affinity ligands (monovalent display), and effectively avoids the avidity effect.

3.2 pVIII Display (High-Copy Display)

Advantages: The display copy number can reach hundreds to thousands, greatly enhancing the capture of weak-interaction ligands.

3.3 Biopanning

Multiple rounds of “binding–elution–amplification” cycles are performed using target molecules (proteins, cells, or tissues) to enrich specifically binding sequences.

3.4 CRISPR/Cas9-Assisted Library Optimization

The Cas9 system is used for negative screening against the wild-type background to ensure high diversity and accuracy of the library.

4. Core Application Areas

(1) Antibody Drug Development: Construction of fully human scFv, Fab, or VHH (nanobody) libraries for the direct screening of high-affinity antibodies against tumor targets and viral proteins.

(2) Peptide Drug Screening: Identification of biologically active agonists or antagonists using random 7-mer, 12-mer, or cyclic peptide libraries.

(3) Antigen Epitope Mapping: Characterization of linear or conformational epitopes of pathogen antigens to support vaccine design and diagnostic reagent development.

(4) Protein-Protein Interaction Studies: Screening of ligands that specifically bind target proteins and analysis of complex metabolic regulatory networks.

5. Project Workflow and Validation

We provide a closed-loop service from strategy design to the delivery of candidate sequences, ensuring high library quality:

(1) Protocol Design and Vector Construction: Customized design of library capacity and diversity.

(2) Library Construction and Packaging: High-efficiency electroporation to guarantee library capacity.

(3) Library Quality Assessment: Determination of PFU/mL for library titer, and verification of sequence coverage and uniformity by NGS (next-generation sequencing).

(4) Biopanning and Enrichment Validation: Evaluation of enrichment efficiency after multiple rounds of screening by ELISA and other methods.

Figure 2 Schematic diagram of the project process for M13 phage display library

6. Gene Editing Project Introduction

6.1 Core Services

(1) Customized Library Construction: Targeted construction of random peptide libraries, mutant libraries, and various antibody libraries.

(2) High-Throughput Library Screening: Multiple screening models based on solid-phase, solution-phase, or cell-surface platforms.

(3) NGS Deep Sequencing Analysis: Bioinformatic analysis of sequence frequency changes before and after screening to precisely identify candidate clones.

6.2 Technical Advantages

(1) High Library Capacity: Conventional libraries reach 10⁹–10¹¹ CFU/mL.

(2) High Fidelity: Optimized primer design and synthesis to minimize bias.

(3) Full-Process Validation: Detailed construction reports, quality inspection reports, and final candidate sequence information.

7. Case Study

Case: Discovery and Mechanistic Characterization of Novel Anti-PD-1 Antibody D12

Project Description: Innovative breakthrough based on the fully human phage display antibody library AMG.

(1) Project Background:

Immune checkpoint inhibitors (e.g., anti-PD-1 antibodies) have become core tools in cancer immunotherapy. However, different antibodies may exhibit unique efficacy and safety profiles due to differences in binding epitopes and mechanisms. In this study, a novel fully human phage display antibody library AMG was constructed, and the anti-PD-1 antibody D12 with a distinct mechanism of action was successfully isolated, providing a new candidate molecule for tumor immunotherapy.

(2) Protocol Design:

The research team designed and constructed the fully human phage display antibody library AMG with the following key features:

Gene Framework: Human high-frequency germline genes IGHV3-23*03 (VH) and IGKV1-39*01 (VL) were used to reduce immunogenicity.

Diversity Design: Diversity was introduced by targeted mutagenesis of the CDR3 regions (VH-CDR3 with 4–7 random amino acids; VL-CDR3 with partial randomization), focusing on key antigen-binding regions.

Library Capacity and Quality: Library capacity of 7.5×10⁹, functional expression rate of approximately 80%, and library quality verified by PCR and Dot Blot.

(3) Experimental Conclusions:

Anti-PD-1 antibody D12 was isolated from the AMG library by affinity screening and characterized in multiple dimensions:

High affinity and binding properties: SPR analysis revealed a K value of 5.4×10⁻⁸ M for D12 scFv, while the IgG format exhibited higher avidity due to bivalency. Cross-reactivity assays confirmed that D12 binds cynomolgus PD-1, supporting preclinical translational studies. Flow cytometry verified the binding of D12 to PD-1 on the surface of activated human T cells, with signal intensity comparable to nivolumab.

Potent blocking activity: Competitive ELISA demonstrated that D12 fully inhibits the interaction of PD-1 with PD-L1 and PD-L2, with EC₅₀ values of 4.4 nM and 12.5 nM, respectively, similar to the potency of nivolumab.

(4) Application Significance:

The unique epitope and mechanism of action of antibody D12 provide differentiated advantages for its clinical development:

Therapeutic potential: D12 may be suitable for tumors with high PD-L1 expression. Its conformational regulatory mechanism could reduce off-target effects and improve safety.

Platform validation: The success of the AMG library highlights the value of rationally designed antibody libraries for discovering innovative antibodies, establishing a technical paradigm for the development of other targets (e.g., CD3, 4-1BB).

Industrial value: This study provides a novel candidate molecule for immunotherapy and strengthens the application prospects of phage display technology in the biopharmaceutical field.

8. References

[1] Smith, G. P. (1985). Filamentous fusion phage: novel expression vectors. Science.

[2] Bradbury, A. R., et al. (2011). Beyond natural antibodies: the power of in vitro display technologies. Nature Biotechnology.

[3] Jiang, W., et al. (2013). RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nature Biotechnology.

[4] Luo, M. L., et al. (2016). The CRISPR-Cas9 system as a tool for editing the genomes of Staphylococcus aureus. Applied and Environmental Microbiology.

[5] Peissert, F., et al. (2022). Selection of a PD-1 blocking antibody from a novel fully human phage display library. Protein Science.

Cooperate With Us

By choosing us, you will gain a highly experienced and technically competent partner in gene editing. We are committed to accelerating your research and projects with professional expertise, rigorous protocols, and efficient communication.

Consult now to get your customized gene editing strategy and quotation!